Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Ivosidenib bulk supplier for pharma manufacturers

Ivosidenib 250 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 250 mg

Reference Brands: Tibsovo (USA/EU)

Category: Oncology Cancer Care

Ivosidenib 250 mg film-coated tablets, an oral IDH1 inhibitor for IDH1-mutated acute myeloid leukaemia and cholangiocarcinoma. For hospital haematology and oncology pharmacies, importers and distributors.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Ivosidenib? List it or send an offer →

Product Description:

Ivosidenib is an oral, selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The mutated enzyme makes an abnormal metabolite, 2-hydroxyglutarate, which blocks normal cell maturation; ivosidenib cuts its production and lets malignant cells differentiate again. It is supplied as 250 mg film-coated tablets. The usual dose is 500 mg once daily, taken as two tablets. It only works in tumours with an IDH1 mutation, which must be confirmed with a validated test before prescribing.

Approved uses include IDH1-mutated acute myeloid leukaemia, newly diagnosed in adults unfit for intensive chemotherapy, often with azacitidine, and in some markets relapsed or refractory disease. It is also used for previously treated, advanced cholangiocarcinoma with an IDH1 mutation, and in some markets for myelodysplastic syndromes. Differentiation syndrome is the key warning in leukaemia and needs prompt corticosteroids. ECGs are checked for QT prolongation. Strong CYP3A4 inhibitors need a dose reduction, inducers are avoided, and so are high-fat meals.

Sourcing notes. Ivosidenib is a recent targeted medicine, so ask how the offered product is registered in your market and whether it is the originator or a generic permitted under local patent rules. A CTD dossier is standard. Confirm the storage condition and ask for zone IVb stability data for tropical markets. Each lot needs a CoA, with a site GMP certificate and a CoPP on file. It is prescription-only and usually dispensed by hospital haematology or oncology pharmacies. Treatment depends on a companion diagnostic, so check which IDH1 test is approved locally. Specify pack size, quantity and remaining shelf life.

Ivosidenib — third party manufacturing & bulk supply

Ivosidenib 250 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ivosidenib is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ivosidenib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ivosidenib →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Ivosidenib is used for the treatment of adult patients with IDH1-mutated acute myeloid leukemia and other IDH1-mutated malignancies, as determined by an FDA-approved diagnostic test.

Ivosidenib is a small-molecule synthetic compound designed to selectively inhibit the mutant IDH1 enzyme involved in abnormal cancer cell metabolism.

The trade name of ivosidenib is Tibsovo.

Ivosidenib (Tibsovo) is manufactured by Servier Pharmaceuticals.

The generic name is ivosidenib.

The brand name is Tibsovo.

Ivosidenib is manufactured in regulated pharmaceutical facilities operated by Servier Pharmaceuticals for the USA, EU, and UK markets.

Related Products

Thioguanine

Strength:
40 mg

Form: Tablets

Reference Brands: Tabloid (USA), Lanvis (EU)

View Details
Toremifene Citrate

Strength:
60 mg

Form: Tablets

Reference Brands: Fareston (USA)

View Details
Tepotinib

Strength:
225 mg

Form: Tablets

Reference Brands: Tepmetko (USA/EU)

View Details
Thiotepa

Strength:
15 mg, 100 mg

Form: Injection

Reference Brands: Thioplex (USA/EU)

View Details
Crizotinib Capsules

Strength:
200mg, 250mg

Form: Capsules

Reference Brands: Xalkori (US/EU)

View Details
Osimertinib Tablets

Strength:
40 mg, 80 mg

Form: Tablets

Reference Brands: Tagrisso (USA/EU)

View Details
Palbociclib Tablet

Strength:
75mg, 100mg, 125mg

Form: Tablets

Reference Brands:

View Details
Ixazomib Capsule

Strength:
2.3mg, 3mg, 4mg

Form: Capsules

Reference Brands: Ninlaro (US/EU)

View Details
Enquire Now

Usually answered within 48 hours | GMP documents shared before you commit

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.
WhatsApp us